TD Cowen Rates Abbott Laboratories (ABT) Buy, $135 Price Target
TD Cowen has reiterated its Buy rating for Abbott Laboratories with a target price of $135, a 28.71% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
TD Cowen rated Abbott Laboratories ($ABT) "Buy" with a $135 price target on October 16, 2026.
ABT
Abbott Laboratories
Key Points
- TD Cowen reiterated its Buy rating on Abbott Laboratories (NYSE: ABT) on October 16, 2026, maintaining a price target of $135.
- TD Cowen's $135 price target implies 28.71% upside from Abbott Laboratories's ($ABT) current $104.89 share price.
- Recently, Abbott shares traded at $104.38, which is below the analyst's average target of $120.71.
- The company has reported a revenue growth of 13.0% year-over-year and has a dividend yield of 2.41%.
Get $ABT trade alerts by text
We text you when insiders, Congress or big funds trade $ABT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Abbott Laboratories alert may contain errors. Disclosures
TD Cowen has reiterated its Buy rating on Abbott Laboratories (NYSE: ABT) on October 16, 2026, maintaining a price target of $135. This is the same target set previously, indicating confidence in the company's future performance despite recent market fluctuations.
TD Cowen vs. the S&P 500
Hypothetical returns from TD Cowen's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Abbott Laboratories
Several other institutional investors have adjusted their positions in Abbott Laboratories. Blackrock Inc. grew its holdings by 6,876,428 shares, ending with 152,563,476 shares valued at about $16.0 billion. Vanguard Capital Management LLC added 801,938 shares for a total of 113,750,994 shares worth approximately $11.9 billion. State Street Corporation increased its stake by 1,352,749 shares, bringing its total to 80,926,234 shares valued at around $8.5 billion. Charles Schwab Investment Management, Inc. saw a significant increase with 14,173,548 shares added, totaling 59,674,507 shares worth about $6.3 billion. Vanguard Portfolio Management LLC also increased its position by 1,073,944 shares, totaling 49,017,866 shares valued at approximately $5.1 billion.
Abbott Laboratories Stock Up 2.5%
As of October 16, 2026, Abbott shares were trading at $104.38. This price is about 1.5% below the 50-day moving average of $105.93 and 20.9% under the 52-week high of $132.03. However, the stock is 27.3% above its 52-week low of $81.97. The current price is also 13.5% below the average target price of $120.71 from analysts, which may suggest potential upside.
$ABT price target
Abbott Laboratories daily closes and this analyst's $135 target. Not advice.
Recent Earnings
Abbott Laboratories reported revenue of approximately $46.6 billion over the trailing twelve months, with a year-over-year revenue growth of 13.0%. The company has a net margin of 11.6% and a return on equity of 10.6%. Its next earnings report is scheduled for October 21, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
8 target cuts vs 0 raises.
-
EPS & revenue
EPS met estimates. Revenue beat estimates by 0.5%.
-
Profit surprise
EBITDA missed by 43 percent. Operating income missed by 19 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
8 target cuts.
-
Earnings quality
Gross margin up 3.7 points. Positive free cash flow.
Earnings Call Summary
Abbott completed its $2.4 billion acquisition of Exact Sciences on March 23 and is integrating the cancer diagnostics business into its portfolio. First quarter results came in slightly ahead, with sales of $11.2 billion, up 3.7 percent on a comparable basis, though the respiratory season was weaker than expected. The company is seeing early signs of volume recovery in Nutrition after price increases, expects Core Lab Diagnostics to accelerate, and is launching new cardiac devices like the Volt pulsed field ablation catheter and TactiFlex Duo. Management remains confident in second half acceleration but is being cautious on near term market conditions.
Guidance Abbott cut full year earnings guidance from $5.68 to $5.48 per share, reflecting $0.20 of dilution from the Exact Sciences acquisition. The company guided full year revenue growth of 6.5 percent to 7.5 percent on a comparable basis including Exact Sciences. For the second quarter, Abbott expects earnings of $1.25 to $1.31 per share. Management said they are being conservative on respiratory season assumptions and expect acceleration in the second half driven by Nutrition recovery, Core Lab Diagnostics growth, and Exact Sciences integration.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Abbott Laboratories
In recent insider transactions, Director John G. Stratton bought 2,000 shares at an average price of $86.82 on May 7, 2026, totaling about $173,640. Officer Louis H. Morrone sold 5,850 shares at an average price of $109.83 on August 11, 2026, amounting to approximately $642,506. CEO Robert B. Ford sold 398,832 shares on August 25, 2026, with a total value of around $46.2 million. Additionally, Officer John A. McCoy Jr. sold 27 shares at $109.54 on September 2, 2026, for a value of about $2,958.
Analysts Set New Price Targets
On October 16, 2026, TD Cowen reiterated its Buy rating for Abbott Laboratories with a price target of $135. Earlier, on October 2, 2026, Rothschild & Co upgraded its rating to Buy with a target of $127. Barclays initiated coverage with an Overweight rating and a target of $120 on October 7, 2026. The consensus among analysts is a strong Buy recommendation based on 26 opinions, with a mean price target of $120.71.
About Abbott Laboratories
Abbott Laboratories, based in Abbott Park, IL, develops and sells a wide range of healthcare products worldwide. The company operates in four key areas: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its strong market position and recent performance make it a company to watch as it prepares for its upcoming earnings report.
Bottom Line
Investors will be watching Abbott Laboratories closely as it approaches its earnings report on October 21, 2026. With TD Cowen maintaining its positive outlook, the focus will be on how the company continues to perform in the competitive healthcare market.
Related Filing Alerts
Source: TD Cowen's rating change on $ABT (Oct 16, 2026). Written by software, not financial advice. How we make alerts